Cancer of the larynx. Aetiological factors and oncogenes;Cáncer de laringe. Factores etiológicos y oncogenes

ORL-DIPS

Volumn 31, Issue 1, 2004, Pages 14-32

  Prades, José ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cancer of the larynx; Epidermal growth factor receptor; Gene p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN P53;

CARCINOGENESIS; DISEASE ACTIVITY; EVOLUTION; GENETIC ANALYSIS; HUMAN; LARYNX CANCER; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; OCCUPATION; ONCOGENE; PATHOGENESIS; REVIEW; TOBACCO; VIRUS INFECTION;

EID: 1642383586     PISSN: 02107309     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Martínez Vidal A. Patología del cáncer de laringe. En: Abelló P, Traserra J. Eds. Otorrinolaringología. Barcelona: Doyma, 1992;561-5.
2. Spector J, Maack R. Cancer of the larynx, ear, and paranasal sinuses. En: Lee K. Eds. Essential Otolaryngology. Head and neck surgery. New York: Elsevier Science Publishing Co., 1991;513-36.
3. Scholnick S, Sun P, Shaw M, Haughey B, El- Mofty S. Frequent loss of heterozygosity for Rb, TP53, and chromosome arm 3p, but not NME1 in squamous cell carcinomas of the supraglotic Larynx. Cancer 1994;73-10:2472-80.
4. Rice H, Spiro H. Current concepts in head and neck cancer. USA: American cancer society, 1989.
5. Ransone L, Verma I. Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol 1990;6:539-57.
6. Almadori G, Cadoni G, Maurizi M, Ottaviani F, Paludetti G, Cattani P, Scambia G. Oncogenesi e cancro della laringe. Acta Otorhinol Ital 1995;15/1 (suppl 46).
7. Monge R, Alvarez Vicent J, Sacristán T. Cáncer de laringe, tendencia temporal de la mortalidad (1952-1992) y predicción futura en España. En: Álvarez Vicent J, Sacristán T. eds. Cáncer de laringe. Ponencia Oficial del XVI Congreso Nacional de la SEORL y Patología Cervico-facial. Madrid: Jarypo Editores- Farma Cusí, 1996;15-9.
8. Cantrell W. The current status of laryngeal cancer. En: Inouye T, Fukuda H, Sato T, Hinohara T. eds. Recent advances in bronchoesophagology. Amsterdam: Excerpta Medica, 1990.
9. Davis M, Smith R. Addressing the most important preventable cause of death. Br Med J 1991;303:732-3.
10. Waterhouse H. Epidemiology. En: Ferlito A. eds. Neoplasms of the larynx. Edinburgh: Churchill Livingstone, 1993;49-64.
11. Vines G. Interaction of alcohol and tobacco in laryngeal cancer. Am J Epidemiol 1982;115:380-8.
12. Segi M. Graphic presentation of cancer incidence by site and by area and population. Nagoya, Japón: Segi Institute of Cancer Epidemiology 1977.
13. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer incidence in five continents. Lyon: IARC, 1987; vol V.
14. Robin E, Powell J, Holme M, Waterhouse H, McConkey C, Robertson E. Cancer of the larynx. London: MacMillan, 1989.
15. DeRienzo P, Greenberg D, Fraire E. Carcinoma of the larynx. Changing incidence in women. Arch Otolaryngol Head Neck Surg 1991;117(6):681-4.
16. Snow B, Clark R, Anderson W. Multimodality therapy for head and neck cancer. Stuttgart: Georg Thieme Verlag, 1992.
17. Maier H, Gewelke U, Dietz A, y cols. Risk factors of cancer of the larynx: Results of the Heidelberg case-control study. Otolryngology Head and Neck Surg 1992;107:577-82.
18. Harrison D. Laryngeal cancer: a preventable disease. En: Ferlito A. Eds. Neoplasms of the larynx. Edinburgh: Churchill Livingstone, 1993;65-68.
19. Falk RT, Pickle LW, Brown LM, y cols. Effect of smoking and alcohol consumption on laryngeal cancer risk in coastal texas. Cancer Res 1989;49:4024-9.
20. Alvarez Vicent J, Romero L. Etiología y precáncer. En: Alvarez Vicent J, Sacristán T. eds. Cáncer de cuerda vocal. Ponencia Oficial de la XXXII Reunión Anual de la SEORL y Patología Cervico-Facial. Barcelona: Farma Cusí, 1995;45-50.
21. Field J, Pavalic Z, Spandidod D, Stambrook P, Jones A, Gluckman J. The role of the p53 tumor suppresor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol. Head Neck Surg 1993;119:1118-22.
22. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, Grandi E, Boiocchi M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992;7:1159-66.
23. Piyathilake C, Hine R, Dasanayke A, Richards E, Freeber L, Vaughn W, Krumdieck C. Effect of smoking on folate levels in buccal mucosa cells. Int J Cancer 1992;52:566-9.
24. Lowry S. Alcoholism in cancer of the head and neck. Laryngoscope 1975;85:1275-8.
25. Cann I, Fried P, Rothman S. Epidemiology of squamous carcinoma of the head and neck. Clin North Am 1985;18:367-88.
26. Flanders D, Rothman S. Interaction of alcohol and tobacco in laryngeal cancer. Am J Epidemiol 1982;115:371-9.
27. Lieber C, Garro A, Leo M, Mak K, Worner T. Alcohol and cancer. Hepatology 1986;6:1005-19.
28. Varmus H. The molecular genetics of cellular oncogenes. Ann Rev Genet 1984;18:553-612.
29. Nonoyama M, Huang C, Pagano J, Klein G, Singh S. DNA of Epstein-Barr virus detected in tissue of Burkitts lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1973;70:3265-568.
30. McCance D. Human papillomaviruses and cancer. Biochim Biophys Acta 1985;823:195-205.
31. Sixbey J, Nedrud J, Raab-Traub N, Hanes R, Pagano J. Epstein-Barr virus replication in oropharyngeal epithelial cells. New Engl J Med 1984;310:1225.
32. Leyraz S, Henle B, Chahinian A. Association of Epstein-Barr virus with tymic carcinoma. New Eng J Med 1985;312:1296.
33. Anwar K, Nakakuki K, Naiki H, Inuzuka M. Ras gene mutations and HPV infections are common in laryngeal carcinoma. Int J Cancer 1993;53:22-8.
34. Pollan M, Lopez-Abente G. Wood related ocupations and laryngeal cancer. Cancer Detect Prev 1995;19:250-7.
35. Pederson A, Hogetuit C, Anderson A. Cancer of the respiratory tract amongst workers at a nickel refinery in Norway. Int J Cancer 1973;12:32-41.
36. Cann C, Fried M, Rothman K. Epidemiology of squamous carcinoma of the head and neck. Otolaryngol Clin North Am 1985;18:367-88.
37. Toral I, Ciliv G, Gursel B, Ozdem C. Androgen receptors in laryngeal carcinoma. Eur Arch Otorhinolaryngol 1990;247:244-6.
38. Mattox E, Von Hoff D, McGuire L. Androgen receptors and antiandrogen therapy for laryngeal carcinoma. Arch Otolaryngol 1984;110:721-4.
39. Ferlito A. Histological classification of larynx and hypopharynx cancers and their clinical implications. Pathologic aspects of 2052 malignant neoplasms diagnosed at the ORL department of Padua University from 1966 to 1976. Acta otolaryngol 1976;342 (suppl):1-88.
40. Ferlito A, Polidoro F. Biological and prognostic implications of the morphologic aspects of inmune reaction in lymph nodes draining head and neck cancers. J Laryngol Otol 1979;93:153-75.
41. Esteban F, Ruiz-Cabello F, Concha A, Perez-Ayala M, Delgado M, Garrido F. Relationship of 4F2 antigen with local growth and metastatic potencial of squamous cell caqrcinoma of the larynx. Cancer 1990;66:1493-8.
42. Graham S, Mettlin C, Marshal J. Dietary factors in the epidemiology of cancer of the larynx. Am J Epidemiol 1981;113:675-80.
43. Hagenauer P. Les laryngites chroniques. Encycl. Med. Chir. Oto-rhino-laryngologie. Parí: Editions Techniques, 1989;20645 C10.
44. Schantz S. Head and neck oncology research. Current opinion in oncology 1994;6:265-71.
45. La Fuente A, Pajol F, Carreto P, Villa J, Cuchi A. Human glutathione S-transferase deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 1993;68:49-54.
46. Rabbits T, Rabbits P: Molecular pathology of chromosomal abnormalities and cancer genes in human tumours. En: Glover D, Hames B. Eds. Oncogenes. Oxford: IRL Press, 1989;67-111.
47. Sandberg A, Tuerc-Carel C, Gemmill R. Chromosomes in solid tumours and beyond. Cancer Res 1988;48:1049-59.
48. Masuda M, Battifora H, Yokota J, Meltzer S, Cline M. Specificity of proto-oncogene amplification in human malignant diseases. Mol Biol Med 1987;4:213.
49. Brodeur G, Seeger G, Sehwab M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
50. Seeger R, Brodeur G, Sather H. Association of multiple copies of the N-myc oncogene with rapid progresison of neuroblastomas. New Engl J Med 1985;313:1111-6.
51. Slamon D, Clark GM, Wong S. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
52. McCormick F, Clark B, la Cour T, Kjeldgaard M, Norskov-Lauritsen L, Nyborg J. A model for the tertiary structure of p21, the product of the ras oncogene. Science 1985;230:78.
53. Liberman T, Nusbaum H, Razon N. Amplification, enhanced expression and possible arrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-47.
54. Stoler A. Genes and cancer. Brit Med Bull 1991;47(1): 64-75.
55. Wyke J. Virus oncogenicity. En: Collier L, Parker T. eds. Topley and Wilson's Principle of Bacteriology, Virology and Genetics. Londres: Arnold Lincon, 1990.
56. Bishop J. Oncogenes. Natl Cancer Inst Monogr 1982;60:155-9.
57. Termin H. Structure, variation and synthesis of retrovirus long terminal repeat. Cell 1981;27:1.
58. Stehehin H, Varmus H, Bishop J. DNA related to the transforming gen of avian sarcoma is present in normal avian DNA. Nature 1976;260:170-3.
59. Bishop J. Molecular themes in oncogenesis. Cell 1991;64:235-48.
60. Weinberg R. Oncogens, antioncogens and the molecular basis of multistep carcinogenesis. Cancer Res 1989;4:3713.
61. Hollywood D, Barton C: Oncogenes and tumour suppressor genes. En: Lemoine N, Neoptolemos J, Cooke T. Eds. Cancer: a molecular approach. Oxford: Blackwell Scientific Publications, 1994;13-41.
62. Land H, Parada L, Weinberg R. Cellular oncogenes and multistep carcinogenesis. Science 1983;222:771-778.
63. Hunter T. Cooperation between oncogenes. Cell 1991;64:249-70.
64. Land H, Parada L, Weibberg R. Tumorigenic conversion of primary embryo fibroblsts requires at least two cooperating oncogenes. Nature 1983;304:596.
65. Browne C: Epidermal growth factor and transforming growth factor alfa. Bailliere's Clinical endocrinology and metabolism 1991 Dic;5(4):553-69.
66. Bishop M. Viral oncogenes. Cell 1985;42:23-9.
67. Waterfield M. Epidermal growth factor and related molecules. Lancet 1989;1:1243-6.
68. Chin I, Reddy E, Gival D. Nucleotid sequence analysis identifies the human c-sis-proto-oncogene as a structural gene for platelet-derived growth factor. Cell 1984;37:123.
69. De Larco J, Todaro G. Growth factors from murine sarcoma virus transformed cells. Proc Natl Acad Sci USA 1978;75:4001-5.
70. Spom M, Roberts A. Autocrine growth factors and cancer. Nature 1985;313:747-51.
71. Dvorak HF. Tumors. Wounds that not heal. New Engl J Med 1986;315:1650-9.
72. Starkey R, Cohen S, Orth D. Epidermal growth factor: identificetion of a new hormone in human urine. Science 1975;189:800-2.
73. Stoscheck C, King L. Functional structural charecteristics of epidermal growth factor and its receptor and their relationship to transforming proteins. J Cell Biochem 1986;31:135-52.
74. Carpenter G. The biochemistry and phisiology of the receptor kinase for epidermal growth factor. Mol Cell Endocrinol 1983;31:1-19.
75. Weber R, Pathak S, Frankhentaler R. Effects of epidermal growth factor on a newly stablished head and neck squamous carcinoma cell line. Otolaryngol Head Neck Surg 1988;99:567.
76. Gullick W, Marsdeen J, Whittle N. Expression of epidermal growth factor receptors on human cervical, ovarian and vulvar carcinomas. Cancer Res 1986;46:285-92.
77. Higashiyama S, Abraham J, Miller J, Fiddes J, Klagsburn M. A heparin-binding growth factor secreted by macrophage like cells that is related to EGF. Science 1991;251:936-9.
78. Sainsbury J, Farndon J, Needham G. Epidermal growth factor receptor as a predictor of early recurrence and death from breast cancer. Lancet 1987;1:1398-402.
79. Hendler F, Shum A, Nanu L. Overexpression of EGF receptors in squamous tumors associated with poor survival. J Cell Biochem 1988;105(suppl 12A, abstr).
80. Neal D, Marsh C, Bennett M. Epidermal growth factor receptors in human bladder cancer: comparisons of invasive and superficial tumors. Lancet 1985;1:366-8.
81. Ozawa S, Ueda M, Ando N. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989;63:2169-73.
82. Scherr CH, Rettenmeir C, Sacca R. The cfms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSG-I. Cell 1985;43:665.
83. Ebina Y, Ellis L, Jarnagin K. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 1985;40:74-1.
84. Yarden Y, Kuang W, Yang F. Human protoncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. E.M.B.O.J. 1987;6:3341.
85. Park M, Dean M, Cooper C. Mechanism of met oncogene activation. Cell 1986;45:895.
86. Martin-Zanca D, Hughes S, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986;319:743.
87. Bargmann C, Hung M, Weinber R. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of pl85. Cell 1986;45:649.
88. Merlino G, Xu Y, Ishii S. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984;224:417.
89. Hunter T, Cooper JA. Protein-tyrosine kynases. Ann Rev Biochem 1985;54:897-930.
90. Moelling K, Pfaff E, Beug H. DNA-binding activity is associated with purified myb proteins form AMV and E26 viruses and is temperature-sensitive for E26ts mutants. Cell 1985;40:983.
91. Adams J. Growth control circuitry and the oncogene connection. Cancer Cell 1990;2:190.
92. Shih TY, Weeks M, Young H. Identification of a sarcoma virus coded phosphoprotein in non producer cells transformed by Kirsten or Harvey murine sarcoma virus. Virol 1979;96:64.
93. Barbacid M. RAS gene. Ann Rev Biochem 1987;56:779-827.
94. Riow G, Barrois M, Sheng ZM. Somatic deletions and mutations of c-Hras gene in human cervical cancers. Oncogene 1988;3:29-33.
95. Satoh M, Hatakeyama S, Soshima M. Inmunohistochemical detection of ras p21 in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pahol 1992;74(4):469-72.
96. Stoler AB. Genes and cancer. Brit Med Bull 1991;47(1):64-75.
97. Lewin B. Oncogenic conversion by regulatory changes in transcription factors. Cell 1991;64:303.
98. Kohl EN, Kanda N, Schreck R. Transformation and amplification of oncogene related sequences in human neuroblastomas. Cell 1983;35:359.
99. Ryan K, Birnie G. Myc oncogenes: the enigmatic family. Biochem J 1996;314:713-21.
100. Thompson C, Challoner P, Neiman P. Expression of the c-myc protoncogene during cellular proliferation. Nature 1986;319:374.
101. Stiles CD, Capone G, Scher C. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 1979;76:1279.
102. Ullrich A, Coussens L, Hayflick J. Human epidermal growth factor receptor DNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-25.
103. Bajaj M, Waterfield M, Schlessinger J. On the tertiary structure of the extracellular domains of the epidermal growth factors and insulin receptors. Biochem Biophys Acta 1987;916:220-6.
104. Downward J, Yarden Y, Mayes E. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-7.
105. Margalis B, Rhee S, Felder S. EGF induce tyrosine phosphorylation of phospholipase C-II. A potential mechanism for EGF receptor signalling. Cell 1988;57:1101-7.
106. Stoscheck C, Soderquist A, Carpenter G. Biosynthesis of the epidermal growth factor receptor in cultured human cells. Endocrinology 1985;116:528-35.
107. Cowley G, Smith J, Gusterson B. Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 1986;53:223-9.
108. Scambia G, Panici P, Battaglia F, Ferrandina G. Receptors for epidermal growth factor and steroid hormones in primary laryngeal tumors. Cancer 1991;67:1347-51.
109. Christensen M, Therkildsen M, Hansen B, Hansen G, Bretlau P. Inmunohistochemical detection of epidermal growth factor receptor in laryngeal squamous cell carcinomas. Acta Otolaryngol (Stockh) 1992;112:734-8.
110. Miyaguchi M, Olofsson J, Hellquist H. Expression of epidermal growth factor receptor in laryngeal dysplasia and carcinoma. Acta Otoloaryngol (Stockh) 1990;110:309-13.
111. Wen Q, Nishimura T, Miwa T, Nagayama I, Furukawa M. Expression of EGF, WGFR and PCNA in laryngeal lesions. The Journal of Laryngology and Otology 1995;109:630-6.
112. Yamamoto T, Kamata N, Kawana H, Shimizu S, Kuroki T. High incidence of amplification of the EGF receptor gene in human squamous carcinoma cell lines. Cancer Res 1986;46:414-6.
113. Ozanne B, Richards S, Hendler F, Burns D, Gusterson B. Over-Expression of the EGF receptor is a hallmark of squamous cell carcinomas. Journal of Pathology 1986;149:9-14.
114. Rubin J, Tweardy D. Elevated levels of transforming growth factor alfa and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer research 1993;53:3579-84.
115. Sturgis E, Sacks P, Masui H, Mendelsohn, Schantz S. Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngology Head and Neck Surgery 1994;633-43.
116. Santon J, Cronin M, McLeod C, Mendelsohn J, Masui H, Gill G. Efects of epidermal growth factor receptor concentrarion on tumorigenicity of A431 cells in nude mice. Cancer Res 1986;46:4701-5.
117. Velu T. Structure, function and transforming potential of the epidermal growth factor receptor. Mol Cell Endocrinol 1990;70:205-16.
118. Duh Q, Gum E, Grend P. Epidermal growth factor receptor in normal and neoplastic thyroid tissue. Surgery 1985;98:1000-7.
119. Battaglia F, Scambia G, Rossi S. Epidermal growth factor receptor in human breast cancer correlation with steroid hormone receptors and axillary lymph node involvement. Europ J Cancer Clin Oncol 1980;24:1685-90.
120. Henler F, Shum-Sin A, Oechsli M. Increased EGFR1 binding predicts a poor survival in squamous tumors. Cancer cells 1989;7:347-51.
121. Neal D, Sharples L, Smith K. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619-25.
122. Mukaida H, Toi M, Hirai T. Clinical significance of the expression of epidermal growth factor and its receptor in oesophageal cancer. Cancer 1991;68:142-8.
123. Battaglia F, Scambia G, Benedetti P. Epidermal growth factor receptor expression in gynecological malignancies. Gynecol Obstet Invest 1989;27:42-44.
124. Baucknecht T, Runge M, Schwall M. Ocurrence of epidermal growth factor receptors in human adnexal tumours and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 1988;29:147-57.
125. Scambia G, Benedetti P, Battaglia F. Significance of epidermal growth-factor receptor in advanced ovarian cancer. Clin Oncol 1992;10:529-35.
126. Maurizi M, Almadori G, Cadoni G. Expression of receptor for epidermal growth factor in cancer of larynx. Act Med Rom 1992;30(1/2):89-96.
127. Maurizi M, Scambia G, Benedetti P. Egf receptor expression in primary squamous laryngeal cancer: correlation with clinico-patological features and prognostic significance. Int J Cancer 1991;52:862-6.
128. Miyaguchi M, Olofsson J, Hellquist H. Inmunohistochemical study of epidermal growth factor receptor in severe dysplasia and carcinoma in situ of the vocal cords. Acta Otolaryngol 1991;111:149-52.
129. Miyaguchi M, Olofsson J, Hellquist H. Expression of epidermal growth factor receptor in epiglottic carcinoma and its recurrence after radiotherapy. Clin Otolaryngol 1991;16:466-9.
130. Santini J, Formento JL, Francoul M, Milano G. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head and Neck 1991;13:132-9.
131. Norris K. Tumor supressor genes. Head and Neck 1992;14:407-14.
132. Sager R. Tumor supressor genes: The purple and the promise. Science 1989;246:1406.
133. Casey G, Lo-Hsueh M, Lopez M, Vogelstein B, Stanbridge E. Growth suppression of human breast cancer cells by the introduction of a wild type p53 gene. Oncogen 1991;6:1791-7.
134. Bookstein R, Shew J, Chen P, Scully P, Lee W. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 1990;247:712-5.
135. Weissman B, Saxon P, Pasquale S, Jones G, Geiser A, Stanbridge E. Introduction of a normal chromosome 11 into a Wilm's Tumour cell line controls its tumorigenic expression. Science 1987;236:175-80.
136. Satoh T, Tanigami A, Yamakawa K. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 1990;50:7184-9.
137. Halevy O, Michalowitz D, Oren M. Different tumor derived p53 mutants exhibit distinct biological activities. Science 1990;250:113-6.
138. Watling DL, Gown AM, Coltrera M. Over-expression of p53 in head and neck cancer. Head and neck 1991;14:437-44.
139. Stratton M. The p53 in human cancer. Eur J Cancer 1992;128(1):293-5.
140. Diller L, Kassel J, Nelson C. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772-81.
141. Reich N, Levine A. Growth regulation of a cellular tumour antigen, p53, in non-transformed cells. Nature 1984;308:199-201.
142. Bischoff J, Friedman P, Marshak D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-ede2. Proc Natl Acad Sci USA 1990;87:4766-70.
143. Braithwait A, Sturzbecher H-W, Addison C, Palmer C, Rudge K, Jenkins J. Mouse p53 inhibits SV 40 origin-dependant DNA replication. Nature 1987;329:458-60.
144. Lane D. P53, guardian of the genome. Nature 1992;358:15-6.
145. Tishler R, Calderwood S, Coleman C, Price B. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993;53:2212-6.
146. Mochón A, Esteban F, Concha A, Ciges M. Expresión del proto-oncogen bcl-2 en el carcinoma epidermoide de laringe. Acta Otorrinolaring 1997;48(1):15-20.
147. Dameron K, Volpert O, Tainsky M. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
148. Fracchiolla N, Pignataro L, Capaccio P, Trecca D, Boletini A, Ottaviani A, Polli E. Multiple genetic lesions in laryngeal squamous cell carcinomas. Cancer 1995;75(6):1292-301.
149. Oren M. P53: the ultimate suppressor gene? FASEB J 1992;6:3169-76.
150. Levine A. The tumor suppresor genes. Ann Rev Biochem 1993;62:623-51.
151. Bartek J, Bartkova J, Vojtesek B. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
152. Hollstein M, Sidransky D, Vogelstein B, Harris C. P53 mutations in human cancer. Science 1991;252:49-53.
153. Fromentel C, Soussi T. Tp53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 1992;4:1-15.
154. Franceschi S, Gloghini A, Maestro R, Barzan L, Bidoli E, Talamini R. Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aerodigestive tract. Int J Cancer 1995;60:872-6.
155. Eliyohn D, Goldfinger N, Pinhasi-Kimbi O. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 1988;3:313-21.
156. Milner J, Medcalf E. Cotranslation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation. Cell 1991;65:765-74.
157. Livingstone L, White A, Sprouse J, Livanos E, Jacks T, Tlsty T. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992;70:923-35.
158. Fan S, El-Deyry W, Bae I. P53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
159. Ennis B, Valveriu E, Lippman M, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, Dickson R. Monoclonal anti-EGF receptor inibit the growth of malignant and non-malinan human mammary epitelial cell. Mol Endocrinol 1989;3:1830-8.